Journal of Thoracic Oncology最新文献

英文中文

PP01.06: Electronic Cigarette and Heated Tobacco Product Use and Their Association with Tobacco Control Factors among Adults in Costa Rica, Malaysia, Mauritania, Mexico, and South Africa PP01.06：哥斯达黎加、马来西亚、毛里塔尼亚、墨西哥和南非成年人中电子烟和加热烟草产品的使用及其与烟草控制因素的关系

IF 20.8 1区医学 Q1 ONCOLOGY

Journal of Thoracic Oncology

Pub Date : 2026-01-01 Epub Date: 2026-01-15 DOI: 10.1016/j.jtho.2025.12.023

Chandrashekhar T. Sreeramareddy

引用次数: 0

PP01.52: Improving Adherence to EGFR Inhibitors: A Multidisciplinary Approach Integrating Nail Bracing for Nail Toxicity Management PP01.52：提高EGFR抑制剂的依从性：多学科方法整合指甲支架治疗指甲毒性管理

IF 20.8 1区医学 Q1 ONCOLOGY

Journal of Thoracic Oncology

Pub Date : 2026-01-01 Epub Date: 2026-01-15 DOI: 10.1016/j.jtho.2025.12.054

Cindy Ying-Ying Kang , Ming-Yan Hung , Ching-Yao Wang , Chun-Hsiang Hsu , You-Cheng Jiang , Renin Chang , Min-Hsi Lin

引用次数: 0

PP01.15: Neoadjuvant Chemo-Immunotherapy versus Chemo-TKI in Resectable EGFR-Mutant NSCLC PP01.15：新辅助化疗-免疫治疗与化疗- tki治疗可切除的egfr突变型NSCLC

IF 20.8 1区医学 Q1 ONCOLOGY

Journal of Thoracic Oncology

Pub Date : 2026-01-01 Epub Date: 2026-01-09 DOI: 10.1016/j.jtho.2025.12.093

Jiefei Han, Yali Wang, Wenbin Li

引用次数: 0

Meeting Announcements 会议公告

IF 20.8 1区医学 Q1 ONCOLOGY

Journal of Thoracic Oncology

Pub Date : 2026-01-01 Epub Date: 2026-01-08 DOI: 10.1016/S1556-0864(25)02917-X

引用次数: 0

Tobacco News Update—From the IASLC Tobacco Control Committee 烟草新闻更新-来自IASLC烟草控制委员会

IF 20.8 1区医学 Q1 ONCOLOGY

Journal of Thoracic Oncology

Pub Date : 2026-01-01 Epub Date: 2026-01-08 DOI: 10.1016/j.jtho.2025.11.013

引用次数: 0

Active Surveillance of Multifocal Ground-Glass Opacities: Results of a Prospective Multicenter Trial (ECTOP1021) 主动监测多焦磨玻璃混浊：一项前瞻性多中心试验的结果（ECTOP1021）。

IF 20.8 1区医学 Q1 ONCOLOGY

Journal of Thoracic Oncology

Pub Date : 2026-01-01 Epub Date: 2025-09-20 DOI: 10.1016/j.jtho.2025.09.011

Haoxuan Wu MD , Fangqiu Fu MD , Ting Ye MD , Hong Hu MD , Qiufeng Yu MD , Huawei Zhang MD , Feng Jiang MD , Qingping Song MD , Junjie Ma MD , Tao Hei MD , Yiyun Cheng MD , Minqiang Gong MD , Shengping Wang MD , Yajia Gu MD , Yuan Li MD , Wenli Wu MD , Yang Zhang MD , Haiquan Chen MD, PhD

Introduction

This study aimed to evaluate the safety of active surveillance and establish an individualized management approach for multifocal ground-glass opacities (GGOs).

Methods

This prospective multicenter trial (ECTOP1021, NCT06097910) enrolled patients with more than or equal to three GGOs (tumor diameter ≤ 2 cm, consolidation-to-tumor ratio ≤ 0.25). The primary end point was 5-year overall survival; secondary end points included lesion progression. The surgical curative time window was defined as tumor diameter less than or equal to 2.0 cm and consolidation-to-tumor ratio less than or equal to 0.25, a safe radiologic profile during which patients could achieve definite cure after resection.

Results

A total of 406 patients were recruited from five centers. The cohort consisted predominantly of females (75.6%) and never smokers (87.2%), with a median age of 53 years. In total, 1496 lesions were under surveillance, with a median of three GGOs per patient. The median diameter of the dominant lesion was 0.8 cm. At a median follow-up of 35.4 months, the 5-year overall survival was 100%. Progression occurred in 8.1% of patients, whereas 1.5% developed new lesions. The median increase in tumor diameter was 0.3 cm. Eight patients underwent surgery after enrollment, all pathologic stage IA1; four had invasive adenocarcinoma and four had minimally invasive adenocarcinoma. Patients were categorized into three groups based on estimated lung function loss if complete resection, with tailored strategies accordingly.

Conclusions

Active surveillance within the surgical curative time window seems to be safe and feasible for patients with multifocal GGOs in the short term. It offers an alternative to immediate surgery and rationalized individualized, scenario-based management strategies.

本研究旨在评估主动监测的安全性，并建立多焦磨玻璃混浊症（GGOs）的个性化管理方法。方法：本前瞻性多中心试验（ECTOP1021, NCT06097910）纳入≥3例ggo（肿瘤直径≤2cm，实变-肿瘤比[CTR]≤0.25）患者。主要终点是5年总生存期；次要终点包括病变进展。手术治愈时间窗定义为肿瘤直径≤2.0 cm, CTR≤0.25，这是一个安全的放射学特征，在此期间患者可以在切除后获得明确的治愈。结果：共从5个中心招募了406名患者。该队列主要由女性（75.6%）和从不吸烟者（87.2%）组成，中位年龄为53岁。总共有1496个病变受到监测，平均每个患者有3个ggo。优势病变的中位直径为0.8 cm。中位随访35.4个月，5年总生存率为100%。8.1%的患者出现进展，而1.5%的患者出现新的病变。肿瘤直径中位数增加0.3 cm。8例患者入组后接受手术，病理分期均为IA1；4例为侵袭性腺癌，4例为微创性腺癌。根据完全切除后估计的肺功能损失将患者分为三组，并相应地制定相应的策略。结论：对于多灶性ggo患者，在手术治疗时间窗内进行主动监测在短期内是安全可行的。它提供了即时手术和合理化的个性化、基于场景的管理策略的替代方案。

{"title":"Active Surveillance of Multifocal Ground-Glass Opacities: Results of a Prospective Multicenter Trial (ECTOP1021)","authors":"Haoxuan Wu MD , Fangqiu Fu MD , Ting Ye MD , Hong Hu MD , Qiufeng Yu MD , Huawei Zhang MD , Feng Jiang MD , Qingping Song MD , Junjie Ma MD , Tao Hei MD , Yiyun Cheng MD , Minqiang Gong MD , Shengping Wang MD , Yajia Gu MD , Yuan Li MD , Wenli Wu MD , Yang Zhang MD , Haiquan Chen MD, PhD","doi":"10.1016/j.jtho.2025.09.011","DOIUrl":"10.1016/j.jtho.2025.09.011","url":null,"abstract":"<div><h3>Introduction</h3><div>This study aimed to evaluate the safety of active surveillance and establish an individualized management approach for multifocal ground-glass opacities (GGOs).</div></div><div><h3>Methods</h3><div>This prospective multicenter trial (ECTOP1021, NCT06097910) enrolled patients with more than or equal to three GGOs (tumor diameter ≤ 2 cm, consolidation-to-tumor ratio ≤ 0.25). The primary end point was 5-year overall survival; secondary end points included lesion progression. The surgical curative time window was defined as tumor diameter less than or equal to 2.0 cm and consolidation-to-tumor ratio less than or equal to 0.25, a safe radiologic profile during which patients could achieve definite cure after resection.</div></div><div><h3>Results</h3><div>A total of 406 patients were recruited from five centers. The cohort consisted predominantly of females (75.6%) and never smokers (87.2%), with a median age of 53 years. In total, 1496 lesions were under surveillance, with a median of three GGOs per patient. The median diameter of the dominant lesion was 0.8 cm. At a median follow-up of 35.4 months, the 5-year overall survival was 100%. Progression occurred in 8.1% of patients, whereas 1.5% developed new lesions. The median increase in tumor diameter was 0.3 cm. Eight patients underwent surgery after enrollment, all pathologic stage IA1; four had invasive adenocarcinoma and four had minimally invasive adenocarcinoma. Patients were categorized into three groups based on estimated lung function loss if complete resection, with tailored strategies accordingly.</div></div><div><h3>Conclusions</h3><div>Active surveillance within the surgical curative time window seems to be safe and feasible for patients with multifocal GGOs in the short term. It offers an alternative to immediate surgery and rationalized individualized, scenario-based management strategies.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"21 1","pages":"Pages 150-159"},"PeriodicalIF":20.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145125010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CEACAM7 Expression and DNA Methylation: Prognostic Biomarkers for Lung Adenocarcinoma in African Americans CEACAM7表达和DNA甲基化：非裔美国人肺腺癌的预后生物标志物

IF 20.8 1区医学 Q1 ONCOLOGY

Journal of Thoracic Oncology

Pub Date : 2026-01-01 Epub Date: 2025-08-22 DOI: 10.1016/j.jtho.2025.08.015

Alicia Hulbert MD , Richies Tiv BS , Brent Cao MD , Daniel Cesario MD , Apurva Mallisetty MS , Eric Gauchat MS , Ajay Rana PhD , Frank Weinberg MD , Ludmila Danilova PhD , Ignacio Jusue-Torres MD

Introduction

The goals of this study were to identify lung cancer biomarkers specific to African Americans (AA) by conducting a genome-wide analysis and to understand the role of these biomarkers in overall survival.

Material and Methods

All cancers studied by The Cancer Genome Atlas were queried with the TCGAbiolinks R package (RRID:SCR_017683) for mRNA expression, DNA methylation, and clinical data. Differential expression analysis was performed comparing mRNA expression between AA and Whites. Survival duration differences were studied using the 2-tailed log-rank test. Association with survival was quantified using hazard ratios with 95% confidence intervals with univariate and multivariate Cox proportional hazard models. Spearman’s rank correlation analysis was used to identify CpG sites correlated with mRNA expression.

Results

CEACAM7 was the only gene overexpressed among AA compared with Whites with lung adenocarcinoma (LUAD), and its RNA expression was significantly associated with cancer stage, overall survival duration, and mortality risk in AA. DNA methylation on CpG probes cg22895231, cg25465322, cg01656853, cg17659920, and cg07940585 was negatively correlated with CEACAM7 mRNA expression, directly associated with survival duration, and inversely associated with mortality risk in AA with LUAD. Median survival was 37.29 months versus not reached for the high versus low CEACAM7 expression groups. The 1-, 2-, and 5-year survival rates for the high versus low CEACAM7 mRNA expression were 80% versus 100%, 50% versus 100%, and 20% versus 86%, respectively.

Conclusion

CEACAM7 mRNA expression and its DNA methylation may be associated with overall survival duration and mortality risk among AA with LUAD but not in Whites.

本研究的目的是通过进行全基因组分析来确定非洲裔美国人（AA）特有的肺癌生物标志物，并了解这些生物标志物在总体生存中的作用。材料和方法：使用tcgabiollinks R包（RRID:SCR_017683）查询癌症基因组图谱（cancer Genome Atlas， TCGA）研究的所有癌症的mRNA表达、DNA甲基化和临床数据。对AA与白种人的mRNA表达进行差异分析。生存期差异采用双尾对数秩检验。采用单因素和多因素Cox比例风险模型，采用95%置信区间的风险比量化与生存率的关联。采用Spearman秩相关分析鉴定与mRNA表达相关的CpG位点。结果：与白种人肺腺癌（LUAD）相比，CEACAM7是AA患者中唯一过表达的基因，其RNA表达与AA患者的肿瘤分期、总生存时间和死亡风险显著相关。CpG探针cg22895231、cg25465322、cg01656853、cg17659920和cg07940585上的DNA甲基化与CEACAM7 mRNA表达呈负相关，与AA合并LUAD患者的生存时间直接相关，与死亡风险呈负相关。CEACAM7高表达组和低表达组的中位生存期分别为37.29个月和未达到生存期。CEACAM7 mRNA高表达与低表达的1、2和5年生存率分别为80%对100%，50%对100%，20%对86%。结论：CEACAM7 mRNA表达及其DNA甲基化可能与AA合并LUAD患者的总生存时间和死亡风险相关，而与白种人无关。

{"title":"CEACAM7 Expression and DNA Methylation: Prognostic Biomarkers for Lung Adenocarcinoma in African Americans","authors":"Alicia Hulbert MD , Richies Tiv BS , Brent Cao MD , Daniel Cesario MD , Apurva Mallisetty MS , Eric Gauchat MS , Ajay Rana PhD , Frank Weinberg MD , Ludmila Danilova PhD , Ignacio Jusue-Torres MD","doi":"10.1016/j.jtho.2025.08.015","DOIUrl":"10.1016/j.jtho.2025.08.015","url":null,"abstract":"<div><h3>Introduction</h3><div>The goals of this study were to identify lung cancer biomarkers specific to African Americans (AA) by conducting a genome-wide analysis and to understand the role of these biomarkers in overall survival.</div></div><div><h3>Material and Methods</h3><div>All cancers studied by The Cancer Genome Atlas were queried with the TCGAbiolinks R package (RRID:<span>SCR_017683</span>) for mRNA expression, DNA methylation, and clinical data. Differential expression analysis was performed comparing mRNA expression between AA and Whites. Survival duration differences were studied using the 2-tailed log-rank test. Association with survival was quantified using hazard ratios with 95% confidence intervals with univariate and multivariate Cox proportional hazard models. Spearman’s rank correlation analysis was used to identify CpG sites correlated with mRNA expression.</div></div><div><h3>Results</h3><div>CEACAM7 was the only gene overexpressed among AA compared with Whites with lung adenocarcinoma (LUAD), and its RNA expression was significantly associated with cancer stage, overall survival duration, and mortality risk in AA. DNA methylation on CpG probes cg22895231, cg25465322, cg01656853, cg17659920, and cg07940585 was negatively correlated with CEACAM7 mRNA expression, directly associated with survival duration, and inversely associated with mortality risk in AA with LUAD. Median survival was 37.29 months versus not reached for the high versus low CEACAM7 expression groups. The 1-, 2-, and 5-year survival rates for the high versus low CEACAM7 mRNA expression were 80% versus 100%, 50% versus 100%, and 20% versus 86%, respectively.</div></div><div><h3>Conclusion</h3><div>CEACAM7 mRNA expression and its DNA methylation may be associated with overall survival duration and mortality risk among AA with LUAD but not in Whites.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"21 1","pages":"Pages 124-134"},"PeriodicalIF":20.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III NSCLC in Japan: A Multicenter Prospective Study (AYAME) Durvalumab在日本不可切除的III期非小细胞肺癌中的长期安全性和有效性：一项多中心前瞻性研究（AYAME）。

IF 20.8 1区医学 Q1 ONCOLOGY

Journal of Thoracic Oncology

Pub Date : 2026-01-01 Epub Date: 2025-08-18 DOI: 10.1016/j.jtho.2025.08.010

Hirotsugu Kenmotsu MD, PhD , Yoshinobu Saito MD, PhD , Kiichiro Ninomiya MD, PhD , Shinya Uematsu MD , Burak Akdemir PhD , Ayako Fukui MSc , Ryo Koto MHDS , Masakazu Fujiwara PhD , Chikako Iwao PhD , Hiroshi Kitagawa MD, PhD , Ichiro Yoshino MD, PhD , Akihiko Gemma MD, PhD , Tetsuya Mitsudomi MD, PhD , Nobuyuki Yamamoto MD, PhD

Introduction

Based on the PACIFIC trial results, durvalumab after chemoradiotherapy (CRT) is the standard of care for unresectable stage III NSCLC. However, few large-scale studies have prospectively evaluated its long-term effectiveness and safety, including subsequent treatment.

Methods

This multicenter, noninterventional study (AYAME) enrolled patients who were prescribed durvalumab for unresectable stage III NSCLC after CRT (July 2019–December 2020; 52 sites; Japan). Patients received durvalumab for a maximum of 12 months and were prospectively followed up for 3 years, including the post-durvalumab treatment period. Primary end points were real-world progression-free survival (rwPFS), the incidence of interstitial lung disease (ILD), and adverse events of special interest (AESIs).

Results

Of the 529 enrolled patients, 512 received durvalumab and 511 comprised the safety analysis population. The median time to onset of the first presentation or occurrence of ILD was 45.0 days. ILD of any grade occurred in 387 patients (75.7%) over the 3-year study period: grade 3, 57 (11.2%); grade 4, none (0.0%); and grade 5, 9 (1.8%). The most common AESIs of any grade during durvalumab treatment were thyroid dysfunction (12.5%), hepatic dysfunction (7.2%), and colitis (2.0%). No durvalumab treatment-related ILD or AESIs occurred during the post-treatment period. The median [95% confidence interval] rwPFS was 23.2 [18.2, 27.2] months in the effectiveness analysis population (n = 495). rwPFS rates were 62.5%, 54.6%, 49.4%, and 40.4% at 12, 18, 24, and 36 months, respectively.

Conclusions

This first and largest prospective, observational study demonstrated the long-term safety and effectiveness of durvalumab for unresectable stage III NSCLC after CRT in a real-world clinical setting.

Clinical Trial Registration

UMIN000037090 and NCT03995875

基于PACIFIC试验结果，durvalumab化疗（CRT）是不可切除的III期非小细胞肺癌（NSCLC）的标准治疗方案。然而，很少有大规模的研究前瞻性地评估其长期有效性和安全性，包括后续治疗。方法：这项多中心非介入性研究（AYAME）招募了CRT后不可切除的III期NSCLC患者（2019年7月- 2020年12月；日本52个地点）。患者接受杜伐单抗治疗最多12个月，前瞻性随访3年，包括杜伐单抗治疗后的随访期。主要终点是真实世界无进展生存期（rwPFS）、间质性肺疾病（ILD）的发病率和特殊关注不良事件（AESIs）。结果：在529例入组患者中，512例接受durvalumab治疗，511例纳入安全性分析人群。首次出现/发生ILD的中位时间为45.0天。在3年的研究期间，387例（75.7%）患者发生了任何级别的ILD: 357例（11.2%）；4级，无（0.0%）；5,9年级（1.8%）。在durvalumab治疗期间，最常见的AESIs是甲状腺功能障碍（12.5%），肝功能障碍（7.2%）和结肠炎（2.0%）。治疗后未发生杜伐单抗治疗相关的ILD/AESIs。在有效性分析人群（n=495）中，rwPFS的中位数[95%置信区间]为23.2[18.2,27.2]个月。12、18、24、36个月时rwPFS分别为62.5%、54.6%、49.4%、40.4%。结论：这是第一个也是最大的前瞻性观察性研究，证明了在现实世界的临床环境中，durvalumab治疗CRT后不可切除的III期NSCLC的长期安全性和有效性。临床试验注册：UMIN000037090/NCT03995875。

{"title":"Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III NSCLC in Japan: A Multicenter Prospective Study (AYAME)","authors":"Hirotsugu Kenmotsu MD, PhD , Yoshinobu Saito MD, PhD , Kiichiro Ninomiya MD, PhD , Shinya Uematsu MD , Burak Akdemir PhD , Ayako Fukui MSc , Ryo Koto MHDS , Masakazu Fujiwara PhD , Chikako Iwao PhD , Hiroshi Kitagawa MD, PhD , Ichiro Yoshino MD, PhD , Akihiko Gemma MD, PhD , Tetsuya Mitsudomi MD, PhD , Nobuyuki Yamamoto MD, PhD","doi":"10.1016/j.jtho.2025.08.010","DOIUrl":"10.1016/j.jtho.2025.08.010","url":null,"abstract":"<div><h3>Introduction</h3><div>Based on the PACIFIC trial results, durvalumab after chemoradiotherapy (CRT) is the standard of care for unresectable stage III NSCLC. However, few large-scale studies have prospectively evaluated its long-term effectiveness and safety, including subsequent treatment.</div></div><div><h3>Methods</h3><div>This multicenter, noninterventional study (AYAME) enrolled patients who were prescribed durvalumab for unresectable stage III NSCLC after CRT (July 2019–December 2020; 52 sites; Japan). Patients received durvalumab for a maximum of 12 months and were prospectively followed up for 3 years, including the post-durvalumab treatment period. Primary end points were real-world progression-free survival (rwPFS), the incidence of interstitial lung disease (ILD), and adverse events of special interest (AESIs).</div></div><div><h3>Results</h3><div>Of the 529 enrolled patients, 512 received durvalumab and 511 comprised the safety analysis population. The median time to onset of the first presentation or occurrence of ILD was 45.0 days. ILD of any grade occurred in 387 patients (75.7%) over the 3-year study period: grade 3, 57 (11.2%); grade 4, none (0.0%); and grade 5, 9 (1.8%). The most common AESIs of any grade during durvalumab treatment were thyroid dysfunction (12.5%), hepatic dysfunction (7.2%), and colitis (2.0%). No durvalumab treatment-related ILD or AESIs occurred during the post-treatment period. The median [95% confidence interval] rwPFS was 23.2 [18.2, 27.2] months in the effectiveness analysis population (n = 495). rwPFS rates were 62.5%, 54.6%, 49.4%, and 40.4% at 12, 18, 24, and 36 months, respectively.</div></div><div><h3>Conclusions</h3><div>This first and largest prospective, observational study demonstrated the long-term safety and effectiveness of durvalumab for unresectable stage III NSCLC after CRT in a real-world clinical setting.</div></div><div><h3>Clinical Trial Registration</h3><div>UMIN000037090 and NCT03995875</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"21 1","pages":"Pages 160-173"},"PeriodicalIF":20.8,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144959233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PP01.11: Investigating Mediators of ERK Hyperactivation Mediated Toxicity in Lung Adenocarcinoma PP01.11：研究ERK超激活介导的肺腺癌毒性的介质

IF 20.8 1区医学 Q1 ONCOLOGY

Journal of Thoracic Oncology

Pub Date : 2026-01-01 Epub Date: 2026-01-09 DOI: 10.1016/j.jtho.2025.12.090

Katherine M. Sew , Dylan A. Farnsworth , Lok In Josephine Ma , Kelsie Thu , William W. Lockwood

引用次数: 0

PP01.29: Low Dose Durvalumab Consolidation After Definitive Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer – A Real-World Multicentre Experience From India PP01.29：低剂量Durvalumab巩固III期非小细胞肺癌的最终放化疗-来自印度的真实世界多中心经验

IF 20.8 1区医学 Q1 ONCOLOGY

Journal of Thoracic Oncology

Pub Date : 2026-01-01 Epub Date: 2026-01-15 DOI: 10.1016/j.jtho.2025.12.037

Vivek Agarwala , M.V. Chandrakanth , Amit Sharma , Minakshi Roy , Anish Dasgupta , Kaustav Mandal , Himadri Nayak , Moinak Basu , Shubhabrata Kumar , Aparajita Sadhya , Rupam Manna , Pritam Sardar , Nibedita Sen

引用次数: 0

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of Thoracic Oncology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀